Patent · US Active

Vaccine composition containing synthetic adjuvant

US9987355B2 · kind B2 · utility

10Cited by
168References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 28, 2013
Grant dateJun 5, 2018
Priority date—
Expiry dateFeb 14, 2034

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.